ProBioGen partners with Spica Therapeutics for ST101 development
ProBioGen has announced a collaboration with Spica Therapeutics to perform cell line development for ST101, a first-in-class monoclonal antibody designed to selectively deplete immunosuppressive CD163+ tumour-associated macrophages in oncology applications.












